RMD Open
is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases
Impact Factor: 6.2
Citescore: 7.7
All metrics >>
Latest Articles
Rheumatoid arthritis:
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment29 September 2023
Imaging:
HLA-B27 status and inflammatory MRI lesions of the sacroiliac joints: a post hoc analysis in patients without axial spondyloarthritis22 September 2023
Osteoarthritis:
Use of non-surgical treatments on the journey to knee replacement in patients with knee osteoarthritis: a 10-year population-based case-control study22 September 2023
Osteoarthritis:
Comparative effectiveness of pharmacological interventions for hand osteoarthritis: a systematic review and network meta-analysis of randomised trials21 September 2023
Psoriatic arthritis:
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities21 September 2023
Video Abstract
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
Conclusion: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.
Find out moreEULAR Congress 2023
The 2023 EULAR Congress took place on 31 May – 03 June in Milan, Italy as a hybrid event.
The aim of the European Congress of Rheumatology is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, in order to achieve progress in the clinical care of people with rheumatic diseases.
The abstracts from the congress have been published in ARD and are free to read.
Most Read Articles
Rheumatoid arthritis:
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors2 November 2022
Lupus:
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial26 October 2022
Systemic sclerosis:
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort3 November 2022
Inflammatory arthritis:
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis8 February 2023